U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C20H27O2.Zn
Molecular Weight 664.263
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 8
Charge 0

SHOW SMILES / InChI
Structure of TRETINOIN ZINC

SMILES

[Zn++].CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C([O-])=O.CC(\C=C\C2=C(C)CCCC2(C)C)=C/C=C/C(C)=C/C([O-])=O

InChI

InChIKey=OYWXIJJKRYRHIN-DNOYCTHFSA-L
InChI=1S/2C20H28O2.Zn/c2*1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5;/h2*6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22);/q;;+2/p-2/b2*9-6+,12-11+,15-8+,16-14+;

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H27O2
Molecular Weight 299.4272
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 4
Optical Activity NONE

Description

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACCUTANE

Approved Use

Accutane is indicated for the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. “Severe,” by definition, means “many” as opposed to “few or several” nodules. Because of significant adverse effects associated with its use, Accutane should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, Accutane is indicated only for those female patients who are not pregnant, because Accutane can cause severe birth defects.

Launch Date

1982
Primary
RETIN-A

Approved Use

RETIN-A is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

Launch Date

1971
Palliative
TRETINOIN

Approved Use

retinoin Capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. Tretinoin is for the induction of remission only. The optimal consolidation or maintenance regimens have not been defined, but all patients should receive an accepted form of remission consolidation and/or maintenance therapy for APL after completion of induction therapy with tretinoin.

Launch Date

2007
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
314 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4055 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
24 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOTRETINOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Disc. AE: Cheilitis, Skin xerosis...
AEs leading to
discontinuation/dose reduction:
Cheilitis
Skin xerosis
Desquamation
Headache
Skin xerosis
Sources: Page: p.348
1000 mg single, oral
Overdose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources: Page: p.74
unhealthy, 31
n = 1
Health Status: unhealthy
Condition: AIDS
Age Group: 31
Sex: M
Population Size: 1
Sources: Page: p.74
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea
Sources: Page: p.74
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
DLT: Hypercalcemia, Skin toxicity...
Dose limiting toxicities:
Hypercalcemia (grade 4, 22.2%)
Skin toxicity (grade 3, 33.3%)
Anemia (grade 3, 11.1%)
Thrombocytopenia (grade 3, 11.1%)
Emesis (grade 3, 11.1%)
Hypercalcemia (grade 3, 11.1%)
Sources: Page: p.897
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
DLT: Hypercalcemia, Skin toxicity...
Dose limiting toxicities:
Hypercalcemia (grade 4, 4.3%)
Skin toxicity (grade 3, 17.4%)
Emesis (grade 3, 4.3%)
AST/ALT ratio abnormal (grade 3, 4.3%)
Sources: Page: p.897
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.34
unhealthy, 4
n = 16
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 16
Sources: Page: p.34
1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acne
Sources: Page: p.1
Disc. AE: Fetal damage...
AEs leading to
discontinuation/dose reduction:
Fetal damage (grade 4)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Cheilitis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Desquamation Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Headache Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Skin xerosis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Skin xerosis Disc. AE
12.5 mg/kg single, oral
Overdose
Dose: 12.5 mg/kg
Route: oral
Route: single
Dose: 12.5 mg/kg
Sources: Page: p.348
unhealthy, 29
n = 1
Health Status: unhealthy
Condition: Acne
Age Group: 29
Sex: M
Population Size: 1
Sources: Page: p.348
Diarrhea Disc. AE
1000 mg single, oral
Overdose
Dose: 1000 mg
Route: oral
Route: single
Dose: 1000 mg
Sources: Page: p.74
unhealthy, 31
n = 1
Health Status: unhealthy
Condition: AIDS
Age Group: 31
Sex: M
Population Size: 1
Sources: Page: p.74
Anemia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Emesis grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Hypercalcemia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Thrombocytopenia grade 3, 11.1%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Skin toxicity grade 3, 33.3%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Hypercalcemia grade 4, 22.2%
DLT
100 mg/m2 2 times / day multiple, oral
Highest studied dose
Dose: 100 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 9
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 9
Sources: Page: p.897
Skin toxicity grade 3, 17.4%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
AST/ALT ratio abnormal grade 3, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
Emesis grade 3, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
Hypercalcemia grade 4, 4.3%
DLT
80 mg/m2 2 times / day multiple, oral
MTD
Dose: 80 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 80 mg/m2, 2 times / day
Sources: Page: p.897
unhealthy, 4
n = 23
Health Status: unhealthy
Condition: Neuroblastoma
Age Group: 4
Sex: M+F
Population Size: 23
Sources: Page: p.897
Fetal damage grade 4
Disc. AE
1 mg/kg 2 times / day multiple, oral
Recommended
Dose: 1 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 1 mg/kg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acne
Sources: Page: p.1
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
minor
minor
minor
minor
minor
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Acute depression from isotretinoin.
1991 Jul
L-carnitine supplementation in patients with cystic acne on isotretinoin therapy.
1999 Nov
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
1999 Sep
A case of isotretinoin embryopathy with bilateral anotia and Taussig-Bing malformation.
2000 Jul-Sep
Nephrotic syndrome associated with isotretinoin.
2000 Jun
Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
2000 Mar
[Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
2000 May
Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
2000 May-Jun
Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents.
2001 Aug 15
Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2.
2001 Dec 7
[A study of tissue factor expression and hemostatic molecular markers in patients with acute promyelocytic leukemia].
2001 Jan
Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
2001 Jan
Expression and regulation of chicken fibroblast growth factor homologous factor (FHF)-4 during craniofacial morphogenesis.
2001 Mar
Retinoic acid prevents experimental Cushing syndrome.
2001 Oct
Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells.
2001 Oct
All-trans retinoic acid inhibits vascular smooth muscle cell proliferation targeting multiple genes for cyclins and cyclin-dependent kinases.
2001 Sep
Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid.
2001 Sep
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
2002 Aug 1
Sequential induction of embryonic and adult forms of glutamic acid decarboxylase during in vitro-induced neurogenesis in cloned neuroectodermal cell-line, NE-7C2.
2002 Feb
Radiologic features of all-trans-retinoic acid syndrome.
2002 Feb
Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2.
2002 Jul 12
Excentric cleavage products of beta-carotene inhibit estrogen receptor positive and negative breast tumor cell growth in vitro and inhibit activator protein-1-mediated transcriptional activation.
2002 Jun
[Genetic dissection of retinoic acid function in epidermis physiology].
2002 May
Taking advantage of a side effect of isotretinoin.
2003 Mar
Isotretinoin therapy induces DNA oxidative damage.
2005
Isotretinoin (Ro-Accutane) teratogenesis. A case report.
2005
Isotretinoin (13-cis-retinoic acid) associated atrial tachycardia.
2005 Apr
[Receptor-related mechanism of proliferation inhibilion and apoptosis induetion of human tongue squamous cell line Tca8113 by retinoids].
2005 Aug
Retinoic acid induces VEGF gene expression in human retinal pigment epithelial cells (ARPE-19).
2005 Dec
All-trans-retinoic acid accelerates the differentiation of human B lymphocytes maturing into plasma cells.
2005 Dec
Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study.
2005 May
[Erectile dysfunction during isotretinoin therapy].
2005 Nov-Dec
Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells.
2005 Oct
Differential regulation of Toll-like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes.
2006
Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formation.
2006 Jan 24
[Mechanism of receptor for retinoids inducing apoptosis of human melanoma cell line A375].
2006 Jul
Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells.
2006 Jul
13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes.
2006 Oct
Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective.
2007 Feb
Cerebral ischemia probably related to isotretinoin.
2007 Jun
CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
2007 Nov
13-cis-retinoic acid induces apoptosis by modulating caspase-3, bcl-2, and p53 gene expression and regulates the activation of transcription factors in B16F-10 melanoma cells.
2008
Use of oral isotretinoin in photoaging therapy.
2008 Jan-Feb
[Isotretinoin embryopathy. Report of one case].
2008 Jun
Sacroiliitis and polyneuropathy during isotretinoin treatment.
2008 Mar
Hypercalcemia and osteoblastic lesions induced by 13-Cis-retinoic acid mimicking relapsed neuroblastoma.
2009 Oct
Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by 13-cis-retinoic acid is mediated by the antiapoptotic Bcl-2 family proteins.
2010 Dec
Onset of Kleine-Levin Syndrome in association with isotretinoin treatment.
2010 Jun
Psychiatric reactions to isotretinoin in patients with bipolar disorder.
2010 May
Sacroiliitis and severe disability due to isotretinoin therapy.
2010 May
Patents

Sample Use Guides

acute promyelocytic leukemia (APL): The recommended dose is 45 mg/m2/day administered as two evenly divided doses until complete remission is documented. Therapy should be discontinued 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first. acne vulgaris: RETIN-A Gel, Cream or Liquid should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Liquid: the liquid may be applied using a fingertip, gauze pad, or cotton swab. If gauze or cotton is employed, care should be taken not to oversaturate it, to the extent that the liquid would run into areas where treatment is not intended. Gel: Excessive application results in “pilling” of the gel, which minimizes the likelihood of over application by the patient.
Route of Administration: Other
Human bronchial SMCs were used and pretreated with or without tretinoin, also known as all-trans-retinoic acid (ATRA), (2 μM) for 20 min before the addition of PDGF (1 μg/ml), or ATRA alone. The neutral comet assay, which determines the incidence of double-stranded DNA breaks, was used to demonstrate that ATRA treatment induced apoptosis of bovine and human pulmonary artery SMC. In contrast, apoptotic cell death was not produced in response to ATRA in human bronchial airway SMC, as monitored by comet assay. Similarly, TUNEL assay and the measurement of mitochondrial membrane potential failed to demonstrate significant apoptosis by ATRA in airway SMCs. Positive controls, daunorubicin (DNR) and hydrogen peroxide, effectively elicited apoptosis in airway SMC. Because ATRA inhibited both morphologic and actin cytoskeletal changes induced by PDGF, it was characterized the effects of ATRA on PDGF-induced airway SMC migration using a modified Boyden chamber assay, which allows for determination of motility in random directions. PDGF caused a 4-fold increase in migration of airway SMCs after 24 h, and ATRA blocked these events. ATRA by itself had no effect. While the therapeutic level of ATRA in human plasma could reach 1–2 μM, the effects on airway SMC migration were observed with ATRA concentrations as low as 0.2 μM. DMSO, which is used as vehicle for ATRA and other retinoids, has no effect on PDGF-induced airway SMC migration. This does not appear to be due to the effects of ATRA on cell proliferation, as MTT assay showed that ATRA is not effective in inhibiting PDGF-induced cell proliferation; additionally, migration assay with 4 h of PDGF treatment also exhibits the ability of ATRA to inhibit migratory responses, as monitored using a modified Boyden chamber assay. Thus, although ATRA is ineffective in inhibiting proliferation and inducing apoptosis of airway SMCs, ATRA is an efficient inhibitor of airway SMC migration. Furthermore, using actinomycin D, a general inhibitor of gene transcription, showed that ATRA inhibition of SMC migration does not mediate gene transcriptional events.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:44:10 GMT 2023
Edited
by admin
on Sat Dec 16 05:44:10 GMT 2023
Record UNII
7A9179CU3G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRETINOIN ZINC
Common Name English
RETINOIC ACID, ZINC SALT
Common Name English
Code System Code Type Description
FDA UNII
7A9179CU3G
Created by admin on Sat Dec 16 05:44:10 GMT 2023 , Edited by admin on Sat Dec 16 05:44:10 GMT 2023
PRIMARY
PUBCHEM
22013415
Created by admin on Sat Dec 16 05:44:10 GMT 2023 , Edited by admin on Sat Dec 16 05:44:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID00226884
Created by admin on Sat Dec 16 05:44:10 GMT 2023 , Edited by admin on Sat Dec 16 05:44:10 GMT 2023
PRIMARY
CAS
75980-27-7
Created by admin on Sat Dec 16 05:44:10 GMT 2023 , Edited by admin on Sat Dec 16 05:44:10 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY